Ikaika Therapeutics
PrivateLast Round
VC Round
Oct 7, 2021
Company Overview
Ikaika Therapeutics is a biotechnology company that develops first-in-class antibody therapies to prevent fibrosis and preserve organ function in patients with muscular dystrophy and other fibrotic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ikaika Therapeutics Comparables
Compare Ikaika Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tribune Therapeutics | 77% | |
| Bristol Myers Squibb | 74% | |
| Mediar Therapeutics | 72% | |
Ikaika Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Oct 7, 2021 |
Ikaika Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Qral Ventures | VC Round |
Ikaika Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Ikaika Therapeutics's valuation, stock price, and market status.